Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(TEVA)
My previous session
Most popular
  Report  
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Teva Pharmaceutical Industries : FDA Approves Teva's Migraine Drug Ajovy -- Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2018 | 08:21pm EST

By Maria Armental

The U.S. Food and Drug Administration has approved for sale Teva Pharmaceutical Industries Ltd.'s (TEVA, TEVA.TV) migraine drug Ajovy, the latest in a new class of drugs that target a brain chemical known as CGRP.

Researchers have found that CGRP, which stands for calcitonin gene-related peptide, is involved in the brain's pain-signaling during migraines.

Ajovy should be available in about two weeks, Teva said, and its wholesale-acquisition cost--an industry term for the price drug companies charge wholesalers--will be about $575 for a 225 mg monthly dose and $1,725 for a 675 mg quarterly dose.

The most common adverse reactions in clinical trials were injection-site reactions, the company said.

Amgen Inc. and Novartis AG's Aimovig, the first of the new type of migraine drugs to hit the U.S. market, was approved in May with a list price of $6,900 a year.

Teva, the world's biggest seller of generic drugs, had been counting on the approval of Ajovy, or fremanezumab, to boost sales.

"The way we recover is Ajovy," Chief Executive Kåre Schultz said last month.

The Israeli drugmaker reported a 14% revenue decline for the first half of the year, which the company has attributed in part to continued pricing pressure in its U.S. generics business and generic competition to multiple-sclerosis drug Copaxone.

Shares, which have outperformed the market with a 21% gain this year, rose 6% to $24.25 in after-hours trading.

Write to Maria Armental at maria.armental@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
02/16TEVA PHARMACEUTICAL INDUSTRIES : to Close 11 More Manufacturing Facilities in 20..
AQ
02/14TEVA PHARMACEUTICAL INDUSTRIES : Generics Maker Teva Turns Toward Biotech
DJ
02/13TEVA PHARMACEUTICAL INDUSTRIES : Shares Fall Sharply on 2018 Misses, Light 2019 ..
DJ
02/13TEVA PHARMACEUTICAL INDUSTRIES : King of Generics Pushes Into Biotech Drugs
DJ
02/13GLOBAL MARKETS LIVE : Google, Activision, Virgin Atlantic, Nissan…
02/13TEVA PHARMACEUTICAL INDUSTRIES LTD : Results of Operations and Financial Conditi..
AQ
02/13TEVA PHARMACEUTICAL INDUSTRIES : Reports Fourth Quarter and Full Year 2018 Finan..
BU
02/12CTI BIOPHARMA : Receives $10 Million Milestone Payment for TRISENOX
AQ
02/07TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. Launch of a Generic Version of S..
AQ
02/07TEVA PHARMACEUTICAL INDUSTRIES : expected to sell Israeli medical equipment plan..
AQ
More news
Financials ($)
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 24,0 $
Spread / Average Target 33%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED19 241
JOHNSON & JOHNSON5.68%365 768
PFIZER-2.86%245 920
ROCHE HOLDING LTD.11.98%233 242
NOVARTIS7.19%228 685
MERCK AND COMPANY4.45%207 536